Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
Business18 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General16 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Business23 hours agoThis artificial intelligence (AI) stock will be the Nvidia of quantum computing by 2035
-
Noosa News18 hours agoLung cancer researchers identify ‘breakthrough’ patterns predictive of treatment success